Is Spravato (Esketamine) Safe with Ketamine?

If you're on Spravato (esketamine) or considering it as an alternative or follow-on to at-home ketamine therapy, this page deserves a slightly different framing than the others in the directory. Spravato is the FDA-approved esketamine nasal spray, which is essentially the S-enantiomer of the same racemic ketamine molecule we use sublingually at Tovani. So the question isn't "is this drug interaction safe" in the usual sense; it's "how do these two related treatments fit together (or not) in a coherent treatment plan." The answer depends on where you are in your treatment journey.

What Spravato actually is

Spravato (esketamine intranasal spray) was FDA-approved in 2019 for treatment-resistant depression and in 2020 for major depressive disorder with acute suicidal ideation or behavior. It's manufactured by Janssen and is the first FDA-approved drug specifically for treatment-resistant depression in over 30 years. The active ingredient, esketamine, is the S-enantiomer of racemic ketamine, the same molecule used in IV and at-home ketamine therapy.

The clinical pharmacology is closely related to (but not identical to) racemic ketamine. Esketamine is roughly 3-4 times more potent than the R-enantiomer at the NMDA receptor, so isolating it produces a more potent NMDA blocker per milligram. The antidepressant effect is the same NMDA-glutamate cascade that racemic ketamine produces. The differences are mostly about formulation, route, and the surrounding clinical infrastructure.

Spravato is dispensed under the FDA Risk Evaluation and Mitigation Strategy (REMS) program: it must be administered in a certified healthcare setting (psychiatric clinic or specialty infusion center), with the patient observed for at least 2 hours after each dose for sedation, dissociation, and blood pressure changes. The standard induction is twice-weekly sessions for 4 weeks, then once-weekly maintenance, then individualized maintenance schedules.

Why "Spravato plus at-home ketamine" isn't a thing

For patients currently in an active Spravato course, Tovani would not also prescribe at-home racemic ketamine. The reason is straightforward: Spravato and racemic at-home ketamine are essentially the same drug delivered differently. Adding the second on top of the first would be running two parallel courses of related medications, which has no documented clinical support, complicates dosing and side-effect attribution, and creates risk for excessive cumulative NMDA antagonism.

This isn't a pharmacologic safety prohibition the way MAOIs are. It's an operational reality that we wouldn't prescribe parallel duplicate treatments any more than we'd prescribe two different SSRIs to the same patient simultaneously. The patient picks one ketamine treatment context (clinic-based Spravato or at-home racemic) and works with that.

The three real patient conversations

Most patients arriving at Tovani with Spravato in their history fall into one of three patterns.

Currently on Spravato, considering switching

This is increasingly common. Patients sometimes try Spravato first because of insurance coverage advantages, then explore at-home ketamine for cost reasons, scheduling convenience, the at-home setting, or because they want to maintain treatment without the clinic-visit burden long-term.

The transition is medically straightforward. There's no required washout from Spravato; you can transition directly from one to the other. Practical steps: complete any planned Spravato sessions you're committed to; coordinate with your Spravato prescriber about discontinuing; start the Tovani intake process. We'll want to know your Spravato treatment history (number of induction and maintenance sessions, response trajectory, side effects) so we can calibrate the at-home approach to your specific picture.

Past Spravato (completed or discontinued), considering at-home

Patients who have completed a planned Spravato course, who responded well and want to continue maintenance with at-home ketamine, or who tried Spravato and either didn't respond or responded with side effects they didn't want to continue managing in a clinic setting. These are all reasonable presentations for at-home ketamine intake.

For patients who responded well to Spravato, at-home ketamine often produces similar response, though the response trajectory may be different (sublingual route, racemic mixture, at-home setting all introduce variables). For patients who didn't respond to Spravato, at-home ketamine sometimes produces meaningful response despite the related pharmacology; the racemic mixture and different route introduce real differences. We tell you honestly that prior Spravato non-response doesn't guarantee at-home non-response but doesn't guarantee response either.

Considering Spravato vs at-home ketamine for the first time

Some patients find Tovani during initial research and want to understand the difference between Spravato and at-home ketamine before choosing. This is a legitimate comparison conversation. The honest framing:

Spravato has FDA approval and the broader insurance-coverage and clinical-validation infrastructure that comes with that. The clinic-based REMS-monitored model provides closer monitoring, which is meaningfully appropriate for some patients (particularly those with significant cardiovascular history, complex psychiatric pictures, or clinical instability that benefits from in-clinic observation).

At-home ketamine through Tovani is meaningfully more affordable, fits into normal life logistics, doesn't require recurring clinic visits, and is appropriate for patients without the specific clinical considerations that warrant the closer monitoring. The clinical evidence base is robust though more about racemic ketamine generally than at-home sublingual specifically.

Neither is universally better. The right choice depends on your specific clinical and life picture. We're happy to have an honest conversation about which fits you better even if the answer is Spravato.

What we do at intake when Spravato is in the history

When a patient mentions Spravato at intake, we ask:

When was your last Spravato session.

How many total sessions you completed in induction and maintenance.

What response you had (suicidality reduction, mood improvement, time to onset, duration of response between sessions).

Whether you had any safety events during Spravato (significant blood pressure elevation, dissociation that was distressing, other side effects).

Whether you have a current relationship with the Spravato prescriber and whether they're aware of your considering at-home ketamine.

The clinical history shapes the at-home onboarding conversation: dose calibration, expected response trajectory, what to watch for that would prompt switching back to a clinic-based setting.

Bottom line

Spravato and at-home racemic ketamine are related interventions in the same therapeutic class, not different drugs that combine well or poorly. Tovani does not prescribe at-home ketamine to patients currently in active Spravato treatment; running parallel courses of related medications isn't supported. For patients considering switching from Spravato to at-home ketamine, or for patients with past Spravato treatment now considering at-home, intake is straightforward with the right clinical history. For patients comparing Spravato versus at-home ketamine for first-time treatment selection, the honest answer is that they fit different clinical and life situations, and the right choice depends on yours.